TRML Tourmaline Corp: רווח למניה בשנים עשר החודשים האחרונים

Tourmaline Bio, Inc. (TRML) focuses on developing innovative antibodies to combat severe inflammation. The 12-month net income per share history demonstrates that the current parameter is -3.41. Simultaneously, the company is implementing "green" standards in its laboratories to reduce toxic waste. Share price growth is expected following the completion of phase II trials for its ophthalmology drug, despite the current lack of revenue.

The stability of Tourmaline Bio, Inc. (TRML) depends on the successful development of the tourmaline-001 antibody to capture the thyroid eye disease treatment niche. This metric aggregates net income over the last 12 months, allocating it per share to assess the actual profitability of the business without accounting for capital dilution. Analyzing the TTM earnings per share chart allows an investor to promptly identify growth stagnation and minimize the risks of deep drawdowns.